U3-1402

Phase 2Small molecule

SSCRI Development Innovations, LLC

U3-1402 is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerCompleted

Breast CancerPhase 2

Completed

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

U3-1402

SSCRI Development Innovations, LLC

Phase 2

3 3

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 4

Tianeptine

Pfizer

Preclinical

1 5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Breast Cancer

NCT04965766

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression

Unknown status·SSOLTI Breast Cancer Research Group·Phase 1·NCT04610528·80 enrolled

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT04699630·121 enrolled

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT04965766·139 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for U3-1402. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — U3-1402 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for U3-1402. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SCRI Development Innovations, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSCRI Development Innovations, LLC

U3-1402

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Breast Cancer3 trials

References

Drug Info

Quick Facts

Related News